[Clinical experience with amikacin (BB-K8) in the urological field (author's transl)].
D000038:Abscess / Q000188:drug therapy; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000613:Aminobutyrates / Q000031:analogs & derivatives / Q000627:therapeutic use; D002908:Chronic Disease; D004341:Drug Evaluation; D004823:Epididymitis / Q000188:drug therapy; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy; D006801:Humans; D007267:Injections; D007273:Injections, Intramuscular; D007612:Kanamycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007709:Klebsiella / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D009920:Orchitis / Q000188:drug therapy; D011467:Prostate; D011469:Prostatic Diseases / Q000188:drug therapy; D011511:Proteus / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011704:Pyelonephritis / Q000188:drug therapy; D013530:Surgical Wound Infection / Q000188:drug therapy; D014526:Urethritis / Q000188:drug therapy; D014570:Urologic Diseases / Q000188:drug therapy*
D000613:Aminobutyrates; D007612:Kanamycin